# A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer

> **NCT01776307** · PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 200 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** BBI608
- **DRUG:** Panitumumab
- **DRUG:** Capecitabine
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT01776307
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2018-06
- **Final completion:** 2020-04
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01776307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01776307, "A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01776307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*